Assyro AI

FDA Orange Book · active-ingredient family

Florbetapir f-18

Florbetapir f-18 is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:AMYVID · NDA 202008

1

Brand (NDA)

0

Generics (ANDA)

2

Listed patents

0

Exclusivity periods

Brand (NDA) products · solution

ProductApplicantApplicationTEApproved
AMYVIDRLD×4AVID RADIOPHARMS INCNDA 202008—Apr 06, 2012

Listed patents (2)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7687052Apr 30, 2027in 11 mo
SubstanceProductU-4217
8506929Apr 30, 2027in 11 mo
SubstanceProductU-4217

Florbetapir f-18 — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo